Bladder Cancer

Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

The FDA approved nogapendekin alfa inbakicept-pmln plus Bacillus Calmette-Guerin for the treatment of certain patients with bladder cancer, according to a press release from the manufacturer.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

The combination of pembrolizumab plus enfortumab vedotin significantly extended OS and PFS as first-line treatment for adults with locally advanced or metastatic urothelial carcinoma, according to the manufacturers of both agents.

Patients with muscle-invasive bladder cancer receiving dose-dense methotrexate, vinblastine, doxorubicin and cisplatinhad improved OS at 5 years compared with gemcitabine and cisplatin, according to a presentation at ASCO Annual Meeting.

Two phase 3 trials that evaluated a nonsurgical therapy for certain patients with bladder cancer met their primary endpoints, according to the agent’s manufacturer.

Men exposed to Agent Orange during their military service had a modestly increased risk for bladder cancer, results of a retrospective study of Vietnam veterans showed.

A series of studies showed that loss of the Y chromosome helps cancer evade the body’s immune system response, resulting in more aggressive bladder cancer in men as they age.

The BCG vaccine appeared associated with a significantly lower rate of and risk for Alzheimer’s disease and related dementias among patients with nonmuscle-invasive bladder cancer, according to data published in JAMA Network Open.

Cardiovascular disease, especially atherosclerotic CVD, was associated with increased risk for cancer diagnosis, according to a study published in JACC: CardioOncology.